Table 2. Results of multivariate survival analysis under inclusion of MHC I expression and UICC-stage as exploratory factors for overall survival in BTC.
| HR | Lower CI (95%) | Upper CI (95%) | P-value | |
|---|---|---|---|---|
| MHC weak (IRS 0–4) | 1 | |||
| MHC moderate (IRS 6–8) | 0.875 | 0.641 | 1.195 | 0.4 |
| MHC strong (IRS 9–12) | 0.661 | 0.442 | 0.989 | 0.04 |
| UICC 1 | 1 | |||
| UICC 2 | 0.971 | 0.584 | 1.612 | 0.9 |
| UICC 3 | 1.73 | 1.085 | 2.759 | 0.02 |
| UICC 4 | 2.398 | 1.495 | 3.847 | <0.001 |
| Total (n=302) |
Abbreviations: BTC=biliary tract cancer; CI=confidence interval; HR= hazard ratio; IRS=immunoreactive score; MHC I=major histocompatibility complex class I; UICC=Union for International Cancer Control.
P-values for testing the statistical significance of individual factors were calculated by Wald test.